[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342072-105":59,"doc-detail-342072-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-5007-in-patients-with-advanced-ret-altered-solid-tumors","First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors","","Oncogenic RET alterations function as an important, tissue-agnostic therapeutic target across multiple cancer types. A first-in-human phase 1 study evaluated SY-5007, a potent and selective RET inhibitor, in 122 patients with RET-altered solid tumors, assessing safety, maximum tolerated dose, and recommended phase 2 dose, alongside pharmacokinetics and early anti-tumor activity. Treatment-related adverse events occurred in 96.7% of patients; objective response rate reached 57.8% with median PFS of 21.1 months.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-5007-in-patients-with-advanced-ret-altered-solid-tumors/342072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/first-in-human-phase-1-dose-escalation-and-dose-expansion-study-of-a-ret-inhibitor-sy-5007-in-patients-with-advanced-ret-altered-solid-tumors/342072.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of this first-in-human phase 1 study of SY-5007?","Question",{"text":112,"@type":113},"To evaluate safety, determine the maximum tolerated dose, and establish the recommended phase 2 dose for SY-5007 in patients with RET-altered solid tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were efficacy and disease control outcomes reported in the study?",{"text":117,"@type":113},"Among efficacy-evaluable patients, the overall objective response rate was 57.8% and the median progression-free survival was 21.1 months.",{"name":119,"@type":110,"acceptedAnswer":120},"What did biomarker analysis of ctDNA reveal about responses?",{"text":121,"@type":113},"In patients with ctDNA-detectable RET alterations, objective response rate was 57.4% and median PFS was 13.8 months, and rapid ctDNA clearance correlated with faster responses and improved outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342072,1790193704,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nFirst-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors  \nWei Li1, Yongsheng Wang2, Anwen Xiong 1, Ge Gao2, Zhengbo Song3, Yiping Zhang3, Dingzhi Huang4, Feng Ye5, Qiming Wang6, Zhihui Li2, Jiaye Liu2, Chunwei Xu3, Yinghui Sun7, Xijie Liu7, Fei Zhou 1 ✉ and Caicun Zhou 1 ✉  \n\n|  | Oncogenic RET alteration is an important, tissue-agnostic therapeutic target across diverse cancers. We conducted a ﬁrst-in-human phase 1 study on SY-5007, a potent and selective RET inhibitor, in patients with RET-altered solid tumors. Primary endpoints were safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) . Secondary endpoints included pharmacokineticsand preliminary anti-tumor activity. A total of 122 patients were enrolled (17 in dose-escalation phase and 105 in dose-expansion phase), including 91 with non-small cell lung cancer, 23 with medullary thyroid cancer, 7 with papillary thyroid cancer and 1 with gastric cancer. Treatment-related adverse events (TRAEs) were reported in 96.7% of patients, with the most common grade ≥ 3 TRAEs being hypertension (22.1%), diarrhea (16.4%), hypertriglyceridemia (6.6%), and neutropenia (6.6%) . The exposure to SY-5007 was dose proportional. Among the 116 efﬁcacy-evaluable patients, the overall objective response rate (ORR) was 57.8%, with 70.0% in treatment-naïve patients and 51.3% in previously treated patients. The median progression-free survival (PFS) was 21.1 months. Efﬁcacy was observed regardless of tumor types and previous therapies. Biomarker analysis of 61 patients with circulating tumor DNA (ctDNA)-detectable RET alterations showed an ORR of 57.4% and median PFS of 13.8 months. Rapid ctDNA clearance of RET alteration correlated with faster responses and improved outcomes. In relapsed patients, off-target induced resistance was observed in 57.1%(12/21), with no on-target RET alterations identiﬁed. In conclusion, SY-5007 was well-tolerated and showed promising efﬁcacy in patients with RET-altered solid tumors. Serial ctDNA monitoring may unveil treatment response and potential |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| resistance mechanisms (NCT05278364) . |  |  |\n|  | Signal Transduction and Targeted Therapy (2024)9:300 ; [https://doi.org/10.1038/s41392-024-02006-9](https://doi.org/10.1038/s41392-024-02006-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nThe REarranged during Transfection (RET) gene encodes a vital transmembrane receptor tyrosine kinase that plays an essential role in various physiological processes. Upon stimulation by glial cell line-derived neurotrophic factor (GDNF) family ligands, speciﬁc tyrosine residues within the RET intracellular domain undergo autophosphorylation, creating docking sites for key adaptor proteins. This process triggers critical signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT, which are integral to cellular functions such as migration, proliferation, survival, and differentiation. These pathways are particularly important during embryogenesis, nervous system development, and renal morphogenesis.1,2 Dysregulation of RET through somatic gene alterations, such as fusions and activating mutations, can lead to its constitutive activation, which result in heightened downstream signaling activation. This persistent activation overactivates downstream signaling, promoting uncontrolled cell growth, resistance to apoptosis, and ultimately contributing to  \ntumorigenesis and metastasis. Consequently, RET has garnered considerable attention as a signiﬁcant target for therapeutic intervention in various malignancies.3–5  \nIn non-small cell lung cancer (NSCLC), RET fusions are ","cbCainBwqBd9USXD","https://ap.wps.com/l/cbCainBwqBd9USXD","pdf",700850,11,"English","# Introduction\n## RET signaling and oncogenic activation\n## RET alterations across cancer types\n# Study overview and outcomes\n## Safety and recommended phase 2 dose\n## Pharmacokinetics and preliminary anti-tumor activity\n## Efficacy metrics and biomarker findings","[{\"question\":\"What was the main purpose of this first-in-human phase 1 study of SY-5007?\",\"answer\":\"To evaluate safety, determine the maximum tolerated dose, and establish the recommended phase 2 dose for SY-5007 in patients with RET-altered solid tumors.\"},{\"question\":\"How were efficacy and disease control outcomes reported in the study?\",\"answer\":\"Among efficacy-evaluable patients, the overall objective response rate was 57.8% and the median progression-free survival was 21.1 months.\"},{\"question\":\"What did biomarker analysis of ctDNA reveal about responses?\",\"answer\":\"In patients with ctDNA-detectable RET alterations, objective response rate was 57.4% and median PFS was 13.8 months, and rapid ctDNA clearance correlated with faster responses and improved outcomes.\"}]","First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors | PDF",1790045043,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d46f2c39a1af0c178d7d5dbfa674676.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38cac731be992bf90e0ac8d2e966fd20.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c4b01a022b46c86f959211005a8a247.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d26f1c5f19a7aa688c6620ab1a24b26.webp",980,1301]